Nervgen pharma announces results of annual general meeting of shareholders

All resolutions submitted for approval were passed by shareholders glenn ives appointed as chair of the board john ruffolo appointed as chair of the audit committee vancouver, british columbia--(newsfile corp. - june 5, 2024) - nervgen pharma corp. (tsxv: ngen) (otcqb: ngenf), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its annual general meeting of shareholders ("agm") held on june 4, 2024. "we appreciate the support demonstrated by our shareholders at this agm," said mike kelly, nervgen's president & ceo.
GM Ratings Summary
GM Quant Ranking